Alan R. Shuldiner, MD is the John L. Whitehurst Professor at the University of Maryland School of Medicine, Associate Dean of Personalized Medicine, Director of the Program for Personalized and Genomic Medicine, and Head of the Division of Endocrinology, Diabetes and Nutrition. He leads a multidisciplinary clinical and translational research program that includes protocols conducted at the Amish Research Clinic in Lancaster, PA, the University of Maryland, and Baltimore Veterans Administration Medical Center.
Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program
Article first published online: 10 MAR 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Special Issue: Implementation of Genomic Medicine
Volume 166, Issue 1, pages 76–84, March 2014
How to Cite
2014. Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet Part C 166C:76–84., , , , , , , , , , , , , , , , , , , , .
Conflict of interest disclosure: Dr. Shuldiner receives support from NIH for anti-platelet pharmacogenomics research, and is a consultant to United States Diagnostic Standards, Inc. and Merck, Inc. Other authors have no conflicts of interest to declare.
* Correspondence to: Alan R. Shuldiner, M.D., University of Maryland School of Medicine, 685 West Baltimore Street, Room 379, Baltimore, MD 21201. E-mail: firstname.lastname@example.org
- Issue published online: 18 MAR 2014
- Article first published online: 10 MAR 2014
- National Institutes of Health. Grant Numbers: U01HL105198, S10OD012357
- University of Maryland School of Medicine
- University of Maryland Medical Center
- individualized medicine;
- personalized medicine;
- translational research;
- implementation science;
- anti-platelet pharmacogenetics
Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non-trivial practical barriers. We implemented a Personalized Anti-platelet Pharmacogenetics Program (PAP3) for cardiac catheterization patients at the University of Maryland Medical Center and the Baltimore Veterans Administration Medical Center Patients' are offered CYP2C19 genetic testing, which is performed in our Clinical Laboratory Improvement Amendment (CLIA)-certified Translational Genomics Laboratory. Results are returned within 5 hr along with clinical decision support that includes interpretation of results and prescribing recommendations for anti-platelet therapy based on the Clinical Pharmacogenetics Implementation Consortium guidelines. Now with a working template for PAP3, implementation of other drug-gene pairs is in process. Lessons learned as described in this article may prove useful to other medical centers as they implement pharmacogenetics into patient care, a critical step in the pathway to personalized and genomic medicine. © 2014 Wiley Periodicals, Inc.